The Most Suitable Dosage Regimen of Antibiotics for MRSA from Economical and Clinical Aspects.

从经济和临床角度分析MRSA最合适的抗生素剂量方案。

基本信息

  • 批准号:
    11672247
  • 负责人:
  • 金额:
    $ 1.34万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    1999
  • 资助国家:
    日本
  • 起止时间:
    1999 至 2000
  • 项目状态:
    已结题

项目摘要

Purpose. The purpose of the study was to evaluate the most suitable dosages and dosing intervals on the basis of pharmacokinetic parameters for three kinds of antibiotics for MRSA infection, vancomycin (VCM), arbekacin (ABK) and teicoplanin (TEIC) from economical and clinical point of view.Methods. On the basis of pharmacokinetic mean-arameters of VCM obtained from Japanese, the computer simulation-study was performed by using one-compartment model analysis. Regarding to ABK and TEIC, the pharmacokinetic study was performed on each plasma concentration obtained from MRSA-patients by using Sawchuk-Zaske method.Results. In the case of VCM, we concluded that 1300 mg of VCM given once daily on commencing treatment of MRSA infection is the most suitable dosage regimen for Japanese adult patients because the regimen enable to increase the most suitable VCM peak concentration of 25-40 ug/mL and traugh level of under 10 ug/mL.In contrast, The dosage recommended in the Japanese version of the V … More CM package insert (500 mg of VCM given four times a day, or 1000 mg of VCM given twice a day) could not satisfy the concentration described above. From the economical point, the two weeks administration of VCM at a dose of 1300 mg once a day is cheaper by \67, 550 than the administration method described in package insert. In the case of ABK, 200 mg of ABK given once a day is found to be the most suitable dasage resimen for Japanese adult patient. Further, the pharmacokinetic parameter of TEIC was examined in 24 of adult MRSA patients. As a result, it was clarified that volume of distribution and clearance for TEIC are 0.6436 L/kg and 0.0018 L/kg/h, respectively. From the result, the administration of TEIC at a dose of 200 mg once a day is not enough to obtain an effective peak concentration of TEIC.The dose of 400 mg a day is found to be the most suitable dosage.The results obtained from the study gave the most useful clue for considering drug administration both from clinical and economical point of views. Less
目的。这项研究的目的是根据经济和临床观点的三种抗生素来评估最合适的剂量和给药间隔。根据从日语获得的VCM的药代动力学均值齐平仪,计算机模拟研究是通过使用一个室内模型分析进行的。关于ABK和TEIC,使用Sawchuk-Zaske Method.Results对从MRSA患者获得的每个血浆浓度进行了药代动力学研究。 In the case of VCM, we concluded that 1300 mg of VCM given once daily on commending treatment of MRSA infection is the most suitable dosage regimen for Japanese adult patients because the regimen enable to increase the most suitable VCM peak concentration of 25-40 ug/mL and traugh level of Under 10 ug/mL.In contrast, The dosage recommended in the Japanese version of the V … More CM package insert (500 mg of VCM每天给出四次,或每天两次给出1000 mg的VCM)无法满足上述浓度。从经济点开始,每天以1300毫克的剂量为1300毫克的两周管理\ 67,550比包装插入中描述的管理方法。就ABK而言,发现每天给予200毫克ABK是日本成年患者最合适的dasage妇女。此外,在24名成人MRSA患者中检查了TEIC的药代动力学参数。结果,澄清的是,TEIC的分布量和清除率分别为0.6436 L/kg和0.0018 L/kg/h。从结果来看,每天以200 mg的剂量给药不足以获得有效的TEIC峰浓度。每天的剂量为400 mg是最合适的剂量。从这项研究中获得的结果给出了最有用的线索,用于考虑从临床和经济观点考虑药物给药。较少的

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Kenji Matsuyama et.al.: "Optimal Dosage Regimen for Vancomycin in Japanese Patient"Journal of Applied Therapeutic Research. (Accepted). (2001)
Kenji Matsuyama 等人:“日本患者万古霉素的最佳剂量方案”应用治疗研究杂志。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Kenji Matsuyama et al.: "Optimal Dosage Regimen for Vancomycin in Japanese Patient"Am.J.Hosp.Pharm.. (投稿中).
Kenji Matsuyama 等人:“日本患者万古霉素的最佳剂量方案”Am.J.Hosp.Pharm..(进行中)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MATSUYAMA Kenji其他文献

MATSUYAMA Kenji的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MATSUYAMA Kenji', 18)}}的其他基金

Evaluation of New Agents modified Vitamin K of anticancer which inhibited cdc 25 phosphatase
抑制cdc 25磷酸酶的修饰维生素K抗癌新剂评价
  • 批准号:
    18590161
  • 财政年份:
    2006
  • 资助金额:
    $ 1.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Arbekacin dosing regimen for children with focusing on its safety
儿童阿贝卡星给药方案注重安全性
  • 批准号:
    18K14993
  • 财政年份:
    2018
  • 资助金额:
    $ 1.34万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Search for circumventors of arbekacin resistance in MRSA produced by microorganisms
寻找微生物产生的 MRSA 中阿贝卡星耐药性的规避者
  • 批准号:
    21580129
  • 财政年份:
    2009
  • 资助金额:
    $ 1.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了